Immune checkpoint modulators, such as anti-CTLA4 and anti-PD antibodies, and cultured immune cells such as CAR-T, have shown unexpected antitumor effects across a broad spectrum of cancer types in recent years [32–34]. This evidence concerns the gene CTLA4 and cancer.